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Background: Inappropriate use and overuse of antibiotics is a serious concern in the treatment of upper respiratory
tract infections (URTIs), especially in developing countries. In recent decades, information disclosure and public reporting
(PR) has become an instrument for encouraging good practice in healthcare. This study evaluated the impact of PR on
antibiotic prescribing for URTIs in a sample of primary care institutions in China.
Methods: A matched-pair cluster-randomized trial was undertaken in QJ city, with 20 primary care institutions
participating in the trial. Participating institutions were matched into pairs before being randomly assigned into a
control and an intervention group. Prescription statistics were disclosed to patients, health authorities, and health
workers monthly within the intervention group, starting from October 2013. Outpatient prescriptions for URTIs
were collected from both groups before (1st March to 31st May, 2013) and after the intervention (1st March to 31st
May, 2014). A total of 34,815 URTI prescriptions were included in a difference-in-difference analysis using multivariate
linear or logistic regression models, controlling for patient attributes as well as institutional characteristics.
Results: Overall, 90% URTI prescriptions required antibiotics and 21% required combined use of antibiotics. More
than 77% of URTI prescriptions required intravenous (IV) injection or infusion of drugs. PR resulted in a 9 percentage
point (95% CI −17 to −1) reduction in the use of oral antibiotics (adjusted RR =39%, P =0.027), while the use of
injectable antibiotics remained unchanged. PR led to a 7 percentage point reduction (95% CI −14 to 0; adjusted
RR =36%) in combined use of antibiotics (P =0.049), which was largely driven by a significant reduction in male
patients (−7.5%, 95% CI −14 to −1, P =0.03). The intervention had little impact on the use of IV injections or
infusions, or the total prescription expenditure.
Conclusions: The results suggest that PR could improve prescribing practices in terms of reducing oral antibiotics and
combined use of antibiotics; however, the impacts were limited. We suggest that PR would probably be enhanced by
provider payment reform, management and training for providers, and health education for patients.
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Inappropriate use and overuse of antibiotics is a serious
concern, especially in developing countries such as
China [1]. It is perhaps the most prominent manifest-
ation of irrational drug prescribing and contributes to
bacterial resistance, which is an emergent threat to the* Correspondence: xpzhang602@163.com
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unless otherwise stated.global population [2-4]. Nosocomial or hospital-acquired
infection of antibiotic-resistant bacteria has the capacity
to increase medical costs, length of hospital stay, and ul-
timately patient mortality [5,6].
Upper respiratory tract infections (URTIs) are one of
the most common health conditions seen by primary
care workers, and the associated overuse of antibiotics
is widespread [7]. In the UK, for example, general
practitioners prescribe antibiotics to 67% of patients
presenting with respiratory infections, including 47%
of those with URTIs [8]. It was estimated that 60% ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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UK are self-limiting conditions [9]. A large cohort study
of antibiotic usage associated with URTI in UK primary
care settings concluded that prophylactic antibiotic pre-
scriptions are unjustified in reducing the risk of serious
complications in URTIs [10].
In China, approximately 75% of patients with seasonal
influenza were estimated to be prescribed with antibiotics,
more than doubled of the maximum rate (30%) recom-
mended by the World Health Organization (WHO) [1].
Several systematic reviews have shown that antibiotics are
of limited effectiveness in the treatment of URTIs [11] and
suggested no benefit in colds [12].
Growing public health concerns regarding the implica-
tions of inappropriate use and overuse of antibiotics
have resulted in global action [13]; China is no excep-
tion. The recent health reform (2009–2011) in China ar-
ticulated specific governance and incentive structures for
public health organisations to address the issues of poor
quality in prescribing, such as the enforcement of an es-
sential medicine list policy and decoupling the nexus
between medicine sales to health worker remuneration
and bonus payments in primary care organisations [14].
Despite this, empirical evidence demonstrates that the
effectiveness of these policy interventions has been short
of expectations [15].
In recent decades, public reporting (PR) has started
to attract attention as a vehicle for improving the per-
formance of health organisations [16-20]. The United
States has led the PR movement, along with the UK
[21]. The rationale behind this approach draws ex-
perience from other industries with theoretical sup-
port from the domains of psychology, economics, and
organizational behaviour. Public release of performance
data is considered a bottom-up intervention compared
with government regulation [22], and is intended to
improve quality of care through imposing a higher
level of transparency and accountability [23]. Frølich
et al. believe that PR can provide both financial and
reputational incentives for health providers to im-
prove quality of care, although contextual factors (at
the levels of the markets and provider organisation)
and characteristics of providers and patients may en-
hance or mitigate their responses to those incentives
[24]. Reputational incentives could also have financial
implications.
This study aims to explore the potential use of PR
for improving the quality of prescribing in primary
care organisations using a social experiment. The study has
important implications, primarily to reduce unnecessary
antibiotic prescription, but also as an analysis of whether
greater transparency leads to improved healthcare out-
comes. Provider-specific comparative performance report-
ing is currently being debated and implemented in a subsetof developed countries, but only in a small group of devel-
oping countries [25]. Scant information is available regard-
ing the effectiveness of PR in primary care settings,
particularly in relation to prescribing behaviours. The con-




This study was undertaken in QJ city of Hubei province,
involving 20 primary care organisations. Hubei has a
population of 58 million and a GDP of 2,225 billion
(Yuan in 2012), ranking in the middle range of all Chinese
provinces. QJ is located in central Hubei, with a land area
of 2,004 km2 and a population of 1 million. The annual
GDP of QJ reached 49.3 billion (Yuan) in 2012, just above
the average level of all cities in Hubei. The majority of
inhabitants in QJ are of Han ethnicity, with about 8,000
from Hui, Tujia, and other ethnic groups.
We selected QJ due to ready access to prescription data
and implementation of intervention measures. Primary
care organisations in QJ have the benefit of an electronic
health information system (HIS). The QJ government has
been very supportive of this project.
Written informed consent was obtained from all par-
ticipants. This study was approved by the Ethical Review
Committee of Tongji Medical College, Huazhong Uni-
versity of Science and Technology (No. IORG0003571).
Experimental design
This research adopted a matched-pair randomized trial
design. The 20 participating primary care organisa-
tions were paired according to their size, geographic
location and economic status, and population serviced.
We considered all the organisational characteristics
presented in Table 1 in the pair-matching process.
The Technique for Order Preference by Similarity to
Ideal Solution (TOPSIS) method was adopted to cal-
culate a summed score from the matching variables
(standardised) for each participating organisation. TOPSIS
is a multi-criteria decision analysis method that esti-
mates the geometric distance between each alternative
and the ideal alternative to a given solution [26]. The
participating organisations were ranked in order ac-
cording to their distances to the positive and the negative
ideal alternatives. Adjacent organisations were paired
and assigned randomly to the intervention and control
groups.
Participants in the intervention group and the control
group were exposed to the same political, financial, and
administrative environments: the only exception being
the intervention measures. Identical training on appro-
priate prescription practice was offered to both interven-
tion and control groups.
Table 1 Characteristics of participating institutions and patients
Characteristics Control group Intervention group
Primary care institutions
Sample size 10 10
Average population serviced (10,000) 4.04 (1.80) 3.83 (1.43)
Number of beds 65.60 (19.61) 60.00 (21.73)
Number of doctors 28.30 (7.42) 26.30 (8.54)
Outpatient visits per year 50199.60 (29236.49) 49108.20 (23171.97)
Inpatient admission per year 1348.60 (499.95) 1482.20 (703.11)
Drug sales revenue per year (10,000 Yuan) 188.87 (100.01) 150.78 (49.66)
Variety of drugs in stock 307.60 (145.97) 377.10 (172.55)
Percentage (%) of drug sales in total revenue 35.73 (21.52) 25.42 (14.89)
Average revenue per doctor (10,000 Yuan) 22.46 (8.90) 27.01 (8.94)
Patients with prescriptions for URTI Pre-intervention Post-intervention Pre-intervention Post-intervention
Sample size 7294 10369 4378 12774
Average age (years) 23.41 (22.52) 23.25 (23.73) 22.36 (22.83) 24.39 (24.48)
Proportion of male patients (%) 47.92 51.10 50.18 48.76
Proportion of patients enrolled with NCMS 81.81 87.36 84.65 87.40
Notes: Data are presented as % or mean (standard deviation) unless otherwise stated. The characteristics of primary care organisations were drawn from the 2012
data before the intervention started. NCMS, New Cooperative Medical Scheme; URTI, Upper respiratory tract infection.
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The intervention measures were designed after consider-
ing the following assumptions [21,27]:
 Patient choice of healthcare providers: patients or
potential consumers would make an informed
choice of their preferred provider(s) based on
reported prescription indicators, exerting consumer
pressure on healthcare providers.
 Use of reported data by regulators and managers:
medical insurance authorities, local health
authorities, and health organisation managers may
use the reported data for decisions in payment
(or reimbursement), health planning, and performance
management, exerting financial and administrative
pressure on healthcare providers (individual or
institutional level).
 Provider efforts to improve quality of care: physicians
and healthcare organisations have intrinsic motivation
to improve quality of care, especially if their quality of
care falls below average.
The PR intervention started in October 2013. Three
elements were included in the PR of this study: prescrib-
ing indicators were calculated using data extracted from
the HIS on a monthly basis; healthcare providers (at both
individual and institution levels) were ranked using the
prescribing indicators and the reports were displayed in a
public space in the primary care organisations in the inter-
vention group; the monthly performance reports andleague tables were submitted to local health authorities
and organisational managers in the intervention group
(see Public reporting package below). The reports also
contained a brief explanation about the purpose of the PR
intervention (i.e., to curb overuse of antibiotics). Adminis-
trative measures (e.g., meetings and newsletters) were
taken to ensure that all prescribers in the intervention
group were aware of the reports. However, there was no
action taken to individually alert patients to the reports,
although these reports (including poster displays and bro-
chures) were readily available every day in a designated
public space.
Public reporting package
1) Timeline: Monthly reporting in the intervention
group started in October 2013, which is still
continuing at the time of writing.
2) Reported indicators: Prescription indicators were
calculated at both individual (physician) and
institutional levels, including:
 Percentage of prescriptions requiring antibiotics
(%) = Number of prescriptions requiring
antibiotics/total number of prescriptions by a
physician (or institution) in one month × 100%.
 Percentage of prescriptions requiring IV
injections (%) = Number of prescriptions
requiring IV injections/total number of
prescriptions by a physician (or institution) in
one month × 100%.
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expenditure of prescriptions/total number of
prescriptions by a physician (or institution) in
one month.
3) Dissemination: Prescribing physicians and hospitals
were ranked in each of the above indicators. The
league tables were publicly available to consumers
and health workers alike, displayed on a bulletin
board in the lobby of outpatient departments. Hard
copies of the reports were also submitted to local
health authorities and presidents of the hospitals in
the intervention group.
4) Update of reports: The reports were updated monthly
and made available on the first week of each month.
To ensure compliance with the intervention, we sent
trained investigators to the intervention sites at random
to monitor the implementation of intervention measures
on a monthly basis.
Data collection
Data pertaining to the characteristics of the participating
organisations were extracted through their respective ad-
ministrative systems prior to commencement of the PR
intervention, covering the entire year of 2012. These in-
cluded population serviced, number of outpatient visits,
number of hospital admissions, bed numbers, number of
doctors, gross revenue, revenue from drug sales, and
revenue from government subsidies. The research team
validated these data in interviews with managers and
reconciled discrepancies as necessary.
Prescription data were drawn from the electronic HIS.
For the purpose of this study, we collected unidentified
prescription data from the participating organisations for a
period of four months prior to the intervention (1st March
to 31st May, 2013) and four months after start of the inter-
vention (1st March to 31st May, 2014). All prescriptions
associated with URTI were identified and collated for data
analyses. The prescription data also contained demo-
graphic information (gender, age, insurance status) of the
patients, tests and examinations ordered by the physicians,
and expenditure in relation to the prescriptions.
Statistical analysis
The prescribing indicators used in this study were
adapted from the WHO/International Network for the
Rational Use of Drugs indicators, which have been used
widely [2,15,28]. We examined the extent to which the
PR intervention changed the prescribing patterns in rela-
tion to those indicators, such as:
1) Percentage of prescriptions requiring antibiotics;
2) Percentage of prescriptions requiring two or more
antibiotics;3) Percentage of prescriptions requiring intravenous
(IV) injection (peripheral IV administration using a
syringe driver [29]);
4) Percentage of prescriptions requiring infusion
(medicines are introduced into a vein or between
tissues by using an infusion pump or bag [29]);
5) Expenditure per patient visit (including consultations,
diagnostic tests, and prescriptions).
A difference-in-difference (DID) estimation of the above
indicators was used in our study to assess the impact of
the PR intervention on prescribing patterns. The DID
method allows us to control confounding influences of in-
dependent variables, as well as imbalance between groups
in baseline (dependent) variables (due to chances of imper-
fect randomisation).
We performed regression modelling for estimation of
the effect size of PR. We reported both unadjusted esti-
mates of effect size and those adjusted for character-
istics of patients (age, sex and enrolment with the New
Cooperative Medical Scheme (NCMS)) and hospitals
(number of beds, number of doctors, population ser-
viced, outpatient visits a year, inpatient admissions per
annum, drug sales revenue per annum, variety of drugs
in stock, percentage of drug sales in total revenue, and
average revenue per doctor).
For binary dependent variables (in relation to indicator
1, 2, 3, and 4), we used logistic regression models. For a
given patient i serviced within organisation j, the prob-
ability pij of the occurrence of a dichotomous outcome
yij (i.e., value 1 for a patient receiving antibiotics, 0
















and report marginal effects, where
 i =1 . . . i patient, j =1. . . j primary care
organisation;
 Tij indicates ith patient receiving a prescription
within jth primary care organisation before or after
intervention (0 before or 1 after);
 Gij indicates ith patient receiving a prescription
within jth primary care organisation that had or had
not implemented PR intervention (0 control or 1
intervention);
 EFFECTij = Tij * Gij , which measures invention
effect and coefficient βe indicates the effect size;
 o =1. . . o patient visit covariate, p =1. . .p primary
care organisation covariate.
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indicator 5, log transformed), we used a least squares
regression model, which can be expressed as:










Xoij and Xpij are the control (independent) variables. In
addition, a dummy variable was generated to measure
the cluster-pair fixed effect. Robust standard errors were
clustered at the organisational level.
Coefficient βe in the regression model 1 and 2 is actually
an estimation of the interaction between intervention and
time, measuring the DID. For all of the outcome indicators,
we conducted subgroup analyses by gender.
All statistical analyses were performed using Stata
(version 10).
Results
Characteristics of participating organisations and patients
Similar characteristics of participating organisations were
shown between intervention and control groups (Table 1).
Each organisation served on average a population of
40,000 and provided 50,000 outpatient consultations
per annum. A total of 34,815 prescriptions for URTI
were deemed eligible for inclusion in the study. Those
patients prescribed with antibiotics had a mean age of
23.6 years (Standard deviation =23.5); about half (49.5%)
of them were male and over 85.9% were enrolled with the
NCMS.
Prescriptions requiring antibiotics
High rates of antibiotic prescription were noted in both
intervention and control groups (Table 2). Prior to theTable 2 Percentage (%) of prescriptions requiring antibiotics
Indicators Control group Intervention group
Pre Post Pre Post
Percentage of prescriptions requiring antibiotics (%)
All antibiotics 95.28 94.74 90.57 87.55
Oral 25.00 24.63 50.98 40.20
Injection 80.25 80.00 48.54 55.57
For male patients 95.57 95.00 90.76 87.56
For female patients 95.03 94.48 90.37 87.53
Percentage of prescriptions requiring two or more antibiotics (%)
All 16.56 22.21 21.68 23.61
For male patients 16.08 22.17 22.21 22.72
For female patients 17.00 22.22 22.5 24.43
Note: data in bold indicate P <0.05; 95% CI, 95% confidence interval.
aPercentage point changes derived from DID regression models.intervention, more than 90% of prescriptions for URTIs
contained antibiotics.
The PR intervention led to only a slight reduction in
the use of antibiotics, in particular for oral administra-
tion of antibiotics: a 9 percentage point reduction in oral
administration of antibiotics was shown (P <0.05).
Paradoxically, there was an increase in the percentage
of prescriptions requiring two or more antibiotics in
both intervention and control groups; however, this in-
crease was 7 percentage points less in the intervention
group compared with that in the control group (P <0.05).
This mainly occurred for male URTI patients (P =0.03),
whereas the effect was statistically insignificant for female
patients.Prescriptions requiring IV injection or infusion
No significant differences were found between the inter-
vention and control groups in the changes in percentage of
prescriptions requiring IV injection or infusion (Table 3).
Overall, the percentage of prescriptions requiring IV injec-
tion or infusion remained high during the period of study,
with 77% to 90% of prescriptions for URTI requiring IV
injection or infusion.Average expenditure per visit
No significant differences were found between the inter-
vention and control groups in average expenditure per
visit (Table 3). Overall, the average expenditure per visit
for URTI patients was low, ranging from 27 to 41 Yuan
(roughly USD$5–7). The average expenditure per visit
measured in the post-intervention period increased
slightly compared to that in the pre-intervention period
in both intervention and control groups. Such increase
was 10% to 15% less in the intervention group than in
the control group. However, the adjusted estimate offor upper respiratory tract infections
Treatment effecta
Unadjusted (95% CI) P Adjusted (95% CI) P
−1.48 (−6.42, 3.45) 0.556 −1.93 (−6.61, 2.75) 0.419
−8.93 (−28.71, 10.86) 0.377 −9.21 (−17.36, −1.07) 0.027
6.02 (−10.81, 22.86) 0.483 4.04 (−5.53, 13.62) 0.407
−1.52 (−6.55, 3.51) 0.553 −2.09 (−6.70, 2.52) 0.374
−1.38 (−6.39, 3.63) 0.589 −2.29 (−6.59, 2.01) 0.296
−4.25 (−13.62, 5.12) 0.374 −6.97 (−13.94, 0.00) 0.049
−5.11 (−14.09, 3.87) 0.265 −7.51 (−14.27, −0.74) 0.030
−3.49 (−13.69, 6.71) 0.502 −6.46 (−14.07, 1.15) 0.096
Table 3 Percentage (%) of prescriptions requiring IV injections and infusions and average expenditure per prescription
for upper respiratory tract infection
Indicators Control group Intervention group Treatment effecta
Pre Post Pre Post Unadjusted (95% CI) P Adjusted (95% CI) P
Percentage of prescriptions requiring IV injection (%)
All 90.00 86.17 81.82 77.89 1.66 (−5.50, 8.83) 0.649 1.23 (−3.82, 6.28) 0.633
Male 90.01 85.75 82.29 78.30 2.05 (−5.77, 9.86) 0.608 1.36 (−4.68, 7.39) 0.659
Female 89.97 86.62 81.34 77.49 1.22 (−5.62, 8.08) 0.725 1.22 (−3.18, 5.62) 0.587
Percentage of prescriptions requiring infusion (%)
All 89.76 85.87 81.45 77.64 1.82 (−5.59, 9.23) 0.630 1.37 (−3.93, 6.67) 0.612
Male 89.81 85.39 81.83 78.02 2.38 (−5.52, 10.27) 0.555 1.72 (−4.32, 7.76) 0.577
Female 89.71 86.39 81.06 77.28 1.20 (−6.00, 8.41) 0.743 1.14 (−3.73, 6.02) 0.645
Average expenditure per prescription (¥ Yuan)
All 27.53 41.21 29.72 37.82 −12.80 (−41.77, 16.17) 0.363 −1.21 (−16.33, 13.90) 0.867
Male 27.60 40.38 29.39 37.74 −10.10 (−38.04, 17.85) 0.455 0.60 (−14.37, 15.57) 0.933
Female 27.46 42.09 30.06 37.89 −15.64 (−45.97, 14.69) 0.290 −3.00 (−18.76, 12.77) 0.692
aPercentage point changes or percentage changes derived from DID regression models.
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Discussion
PR can have an impact on prescription patterns in pri-
mary care settings. This study demonstrated that PR in-
terventions reduced the overall number of prescriptions
associated with oral administrated antibiotics and re-
tarded an anticipated potential rise in combined use of
two or more antibiotics for URTIs. Although clinical
outcomes of such a change were not explored in this
study, it is reasonable to expect a positive outcome.
Overuse of antibiotics is a widespread and serious prob-
lem in China [15,28,30], despite clinical guidelines for
URTIs that advise against routine use of antibiotics [31].
Systematic reviews with meta-analyses of randomised
controlled trials have shown minimal benefit associated
with antibiotic prescriptions for URTIs [12,32,33]. Mean-
while, there are growing concerns about the possibility
of antimicrobial resistance induced by irrational use of
antibiotics. It was estimated that abuse of antibiotics for
URTIs in low- and middle-income countries contributes
to an additional 36% of medical costs [34]. Reducing ir-
rational use of antibiotics can preserve these resources
for more cost-effective interventions.
It is important to note that the overall use of anti-
biotics for URTIs in the participating primary care
organisations remained at a high level despite the PR
interventions. In addition, the PR interventions failed to
show a significant impact on prescriptions using par-
enteral administration (injection and infusion). This
study found that over 87% of prescriptions for URTIs
contained antibiotics, much higher than the WHOrecommendations [1]. The percentage of prescriptions
requiring administration via IV injection and infusion for
URTI reached a staggering level – over 77%. Arguably,
IV injection and infusion are more likely to impose
health risks for the public, leading to iatrogenic and
nosocomial problems such as transmission of blood-
borne viruses and infection of infusion sites [3].
The persistent high prevalence of antibiotic misuse
probably reflects both inertia in physician practice and
continued demand from patients. Nevertheless, many
Chinese patients regard parenteral administration as
integral to high-quality care [3]. The national zero-
mark-up policy, introduced during 2009–2011, prohibits
primary care organisations from generating excessive
profits from retailing drugs, with the intention of making
drugs more financially accessible. Health providers are
wily and resourceful: fees can be charged in relation to
injection or infusion services [35]. This may explain why
the apparent consumer demand for antibiotics continues
to be high, and why prescribing changes were mainly
limited to oral antibiotics.
PR interventions did not have a significant effect on
the average expenditure per visit. One plausible explan-
ation could be that the expenditure had already been
low due to a range of policies. The participating primary
care organisations in both intervention and control
groups had been exposed to the same policy environ-
ments over the past decade. Primary care organisations
are only allowed to stock and provide drugs listed in the
essential medicines list; these drugs can only be purchased
through a regional centralized tendering and purchasing
system at an agreed price; patients (and insurers) are
charged with exactly the same purchasing price for their
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policies have led to a significant reduction in drug expend-
iture [15]. Understandably, the capacity for further reduc-
tion of drug expenditure in primary care organisations is
therefore limited.
There are policy implications arising from this study.
Evidence from randomised control trials is regarded as
the most robust and reliable. It is rare to find a study
that uses a randomised control trial design to test
the effect of PR interventions on physician prescrib-
ing practices within a complex health system and policy
environment [16,17,21].
Internationally, healthcare systems are moving towards
greater transparency and accountability [22]. Perform-
ance reporting in healthcare has been shown to improve
the health systems of developed countries [16,17,21].
Despite this, reporting systems must be properly devel-
oped, considering a system-wide stakeholder participation,
a change of organisational culture, and the accuracy and
relevancy of reported data. It is also important to be mind-
ful of minimising unintended consequences [36].
PR of prescription performance may impose “pressures”
on prescribers arising from consumers, payers, managers,
and colleagues. The magnitude of the pressure depends on
the level of PR awareness and how the population under-
stands it [24,27,37,38].
We fear that consumer pressure to reduce irrational
antibiotic and injectable prescription is limited in China,
as the disclosed prescription indicators are difficult for
consumers to understand due to limited health literacy.
It is unlikely that the general public are either able or in-
clined to use the reported information to identify and
choose healthcare providers. Previous studies show that
consumer health literacy is low in China [39]; overuse of
antibiotics is common; and physicians may be under
pressure to prescribe more, not fewer, antibiotics [1].
The effect of PR on patients may also be jeopardised by
limited exposure of patients to PR.
Pressure from payers is usually linked with financial
incentives (or disincentives) [24,40]. In this study, we
found that the PR interventions are more likely to have
an impact on the use of oral administered antibiotics
compared with those administered via IV injection or in-
fusion. This is perhaps because there are no financial
incentives directly linked to reduction in irrational use
of antibiotics, and fewer prescriptions of oral antibiotics
(with zero-profit attached) are less likely to have a negative
consequence on organisational revenues than reduced
prescriptions of injected antibiotics (where a service fee
can be charged). Clearly, these are demonstrable examples
of perverse incentives.
Pressures from managers and colleagues may be a
major driving force for the impact of PR interventions
on prescribers. The working environment of physiciansin China is characterised by strong administrative inter-
ventions from the government and organisations [41,42].
Physician buy-in of PR is also essential for success; after
all, they make the final prescription decision. Our ex-
perience, together with studies conducted elsewhere
[43], show that physicians may challenge the validity of
the PR and express concerns about performance report-
ing at individual levels for potential misinterpretations
from patients. If a physician believes that the reported
data are flawed (e.g., lack of adequate risk adjustment),
he or she may be less likely to be influenced by the data.
To make PR more acceptable, simplified data presenta-
tion, continued risk-adjustment refinement, and internal
review before PR are necessary [43].
The development of an adequate PR system should be
tailored to the macro- and micro-environment in which
the healthcare organisations are operating [40]. Con-
sumers and health care providers should be involved
in the design and specification of information require-
ments, reporting approach, and communication strat-
egies [23]. An ideal PR system should be able to assist
patients or potential users to make better informed deci-
sions [44]. Such a system should also address concerns
from physicians in order to gain their acceptance [43]. A
high quality information system is also critical for easy
access and quality assurance of data. Translating good
practice from one program to others is a practical ap-
proach for building high quality information systems
[45]. Nevertheless, none of these measures are likely to
take place if the income for services remains as a fee for
service, and opportunities remain that maximise income
through unnecessary drug administration practices.
Limitations
This study was undertaken during an early stage of PR
interventions, which may underestimate the true impact
of the interventions. PR does not have a direct impact on
prescriber behaviours. It may take time for healthcare pro-
viders to understand the rationale underlying the PR inter-
ventions and subsequently to change management and
clinical practices. The mechanisms and long term effect of
PR on prescribing behaviours warrant further studies.
The positive but limited effect of PR on prescription
outcomes might also be indicative of shortfalls in project
design and implementations. For example, this project
included a mixed reporting system at both organisational
and individual levels, which prevents us from exploring
further mechanisms of the effect. Nevertheless, the study
has provided important evidence for further improving
the reporting system.
Conclusions
This study demonstrated that PR interventions reduced
the incidence of oral antibiotic prescription and slowed
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URTIs. However, this effect is limited. Overall, the use of
antibiotics remained at high levels, and the PR interven-
tions failed to make an influence on the frequent use of
injections and infusions as an administration route. The
impact of PR interventions is dependent upon pressures
from consumers, payers, managers, and colleagues. Pa-
tient empowerment mechanisms, financial incentives,
reliable information systems, consumer education, and
prescriber buy-in are required to maximise the impact of
PR interventions.
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